Myasthenia gravis exacerbation after discontinuing mycophenolate

Bjorn Oskarsson, David M. Rocke, Karsten Dengel, David P. Richman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To determine whether discontinuation or marked reduction of mycophenolate mofetil (MMF) in patients with myasthenia gravis (MG) causes MG exacerbations. Methods: We identified 88 patients with MG who took MMF during the 5-year period 2007-2011 at our MG clinic. We then performed detailed chart reviews and recorded all MG exacerbations and their relationship to MMF and other treatment changes. We also recorded demographic data and disease characteristics (including antibody status and Myasthenia Gravis Foundation of America status). Results: There were 14 patients who had an MG exacerbation during the study period. Of these, 13 had discontinued MMF therapy, with a median time until exacerbation of 16 weeks after discontinuation (9 patients) or marked dose reduction (4 patients) of MMF therapy (exacerbation in the absence of change in any other component of the immunosuppressive regimen). Using the cluster option in a Cox regression analysis, the MMF coefficient was -5.32, with a standard error of 1.05 and a p value of 0.0002, corresponding to an estimated hazard ratio of 204. Conclusions: This retrospective cohort study suggests that discontinuation/marked reduction of MMF therapy may increase the risk of MG exacerbation many fold, supporting the hypothesis that MMF plays a role in the maintenance of MG remission/minimal manifestation status. Classification of evidence: This study provides Class IV evidence that in patients with MG taking MMF, discontinuation or marked reduction of MMF causes MG exacerbation.

Original languageEnglish (US)
Pages (from-to)1159-1163
Number of pages5
JournalNeurology
Volume86
Issue number12
DOIs
StatePublished - Mar 22 2016
Externally publishedYes

Fingerprint

Mycophenolic Acid
Myasthenia Gravis
Therapeutics
Immunosuppressive Agents
Cohort Studies
Retrospective Studies
Regression Analysis
Maintenance
Demography

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Myasthenia gravis exacerbation after discontinuing mycophenolate. / Oskarsson, Bjorn; Rocke, David M.; Dengel, Karsten; Richman, David P.

In: Neurology, Vol. 86, No. 12, 22.03.2016, p. 1159-1163.

Research output: Contribution to journalArticle

Oskarsson, Bjorn ; Rocke, David M. ; Dengel, Karsten ; Richman, David P. / Myasthenia gravis exacerbation after discontinuing mycophenolate. In: Neurology. 2016 ; Vol. 86, No. 12. pp. 1159-1163.
@article{2fa545cf99534e719b5f631545dcecb2,
title = "Myasthenia gravis exacerbation after discontinuing mycophenolate",
abstract = "Objective: To determine whether discontinuation or marked reduction of mycophenolate mofetil (MMF) in patients with myasthenia gravis (MG) causes MG exacerbations. Methods: We identified 88 patients with MG who took MMF during the 5-year period 2007-2011 at our MG clinic. We then performed detailed chart reviews and recorded all MG exacerbations and their relationship to MMF and other treatment changes. We also recorded demographic data and disease characteristics (including antibody status and Myasthenia Gravis Foundation of America status). Results: There were 14 patients who had an MG exacerbation during the study period. Of these, 13 had discontinued MMF therapy, with a median time until exacerbation of 16 weeks after discontinuation (9 patients) or marked dose reduction (4 patients) of MMF therapy (exacerbation in the absence of change in any other component of the immunosuppressive regimen). Using the cluster option in a Cox regression analysis, the MMF coefficient was -5.32, with a standard error of 1.05 and a p value of 0.0002, corresponding to an estimated hazard ratio of 204. Conclusions: This retrospective cohort study suggests that discontinuation/marked reduction of MMF therapy may increase the risk of MG exacerbation many fold, supporting the hypothesis that MMF plays a role in the maintenance of MG remission/minimal manifestation status. Classification of evidence: This study provides Class IV evidence that in patients with MG taking MMF, discontinuation or marked reduction of MMF causes MG exacerbation.",
author = "Bjorn Oskarsson and Rocke, {David M.} and Karsten Dengel and Richman, {David P.}",
year = "2016",
month = "3",
day = "22",
doi = "10.1212/WNL.0000000000002405",
language = "English (US)",
volume = "86",
pages = "1159--1163",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Myasthenia gravis exacerbation after discontinuing mycophenolate

AU - Oskarsson, Bjorn

AU - Rocke, David M.

AU - Dengel, Karsten

AU - Richman, David P.

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Objective: To determine whether discontinuation or marked reduction of mycophenolate mofetil (MMF) in patients with myasthenia gravis (MG) causes MG exacerbations. Methods: We identified 88 patients with MG who took MMF during the 5-year period 2007-2011 at our MG clinic. We then performed detailed chart reviews and recorded all MG exacerbations and their relationship to MMF and other treatment changes. We also recorded demographic data and disease characteristics (including antibody status and Myasthenia Gravis Foundation of America status). Results: There were 14 patients who had an MG exacerbation during the study period. Of these, 13 had discontinued MMF therapy, with a median time until exacerbation of 16 weeks after discontinuation (9 patients) or marked dose reduction (4 patients) of MMF therapy (exacerbation in the absence of change in any other component of the immunosuppressive regimen). Using the cluster option in a Cox regression analysis, the MMF coefficient was -5.32, with a standard error of 1.05 and a p value of 0.0002, corresponding to an estimated hazard ratio of 204. Conclusions: This retrospective cohort study suggests that discontinuation/marked reduction of MMF therapy may increase the risk of MG exacerbation many fold, supporting the hypothesis that MMF plays a role in the maintenance of MG remission/minimal manifestation status. Classification of evidence: This study provides Class IV evidence that in patients with MG taking MMF, discontinuation or marked reduction of MMF causes MG exacerbation.

AB - Objective: To determine whether discontinuation or marked reduction of mycophenolate mofetil (MMF) in patients with myasthenia gravis (MG) causes MG exacerbations. Methods: We identified 88 patients with MG who took MMF during the 5-year period 2007-2011 at our MG clinic. We then performed detailed chart reviews and recorded all MG exacerbations and their relationship to MMF and other treatment changes. We also recorded demographic data and disease characteristics (including antibody status and Myasthenia Gravis Foundation of America status). Results: There were 14 patients who had an MG exacerbation during the study period. Of these, 13 had discontinued MMF therapy, with a median time until exacerbation of 16 weeks after discontinuation (9 patients) or marked dose reduction (4 patients) of MMF therapy (exacerbation in the absence of change in any other component of the immunosuppressive regimen). Using the cluster option in a Cox regression analysis, the MMF coefficient was -5.32, with a standard error of 1.05 and a p value of 0.0002, corresponding to an estimated hazard ratio of 204. Conclusions: This retrospective cohort study suggests that discontinuation/marked reduction of MMF therapy may increase the risk of MG exacerbation many fold, supporting the hypothesis that MMF plays a role in the maintenance of MG remission/minimal manifestation status. Classification of evidence: This study provides Class IV evidence that in patients with MG taking MMF, discontinuation or marked reduction of MMF causes MG exacerbation.

UR - http://www.scopus.com/inward/record.url?scp=84961645074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961645074&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002405

DO - 10.1212/WNL.0000000000002405

M3 - Article

C2 - 26850977

AN - SCOPUS:84961645074

VL - 86

SP - 1159

EP - 1163

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -